Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer
Improved understanding of the biological heterogeneity of breast cancer (BC) has facilitated the development of more effective and personalized approaches to treatment. This study describes real-world evidence on treatment patterns and outcomes for a population-based cohort of patients with human ep...
Main Authors: | Eliya Farah, Chantelle Carbonell, Devon J. Boyne, Darren R. Brenner, Jan-Willem Henning, Daniel Moldaver, Simran Shokar, Winson Y. Cheung |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/3/518 |
Similar Items
-
Diagnostic value of IHC and FISH methods for HER2 gene amplification detection in paraffin embedded blocks of breast cancer
by: Seyed Ahmad Aleyasin, et al.
Published: (2023-01-01) -
The Study of HER-2/neu, ER/PR Expression Using Immunohistochemistry (IHC) in the Iraqi Breast Cancer
by: Suhad Faisal Hatem, et al.
Published: (2016-06-01) -
The Discordance Between HER-2/NEU Expression Assessed by Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH): Is It Important to Detect?
by: Berna Bozkurt Duman, et al.
Published: (2014-02-01) -
HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01) -
Potential impact of HercepTest™ mAb PharmDx (Dako Omnis) (ge001) in breast cancer diagnosis
by: Andrzej Marszałek, et al.
Published: (2023-07-01)